Custom vaccine tailored to Patient's tumor enters first human test
NCT ID NCT04266730
Summary
This is a first-in-human safety study for a personalized cancer vaccine called PANDA-VAC. It will be given alongside the immunotherapy drug pembrolizumab to 6 patients with advanced squamous cell lung cancer or head and neck cancer. The vaccine is custom-made for each patient based on the unique mutations found in their tumor, aiming to train the immune system to attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.